<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335716">
  <stage>Registered</stage>
  <submitdate>20/08/2010</submitdate>
  <approvaldate>3/12/2010</approvaldate>
  <actrnumber>ACTRN12610001065088</actrnumber>
  <trial_identification>
    <studytitle>Does Tranexamic Acid reduce transfusion rate in Total Hip Replacements?</studytitle>
    <scientifictitle>In patients undergoing primary total hip replacements for osteoarthritis or avascular necrosis (AVN), does the use of tranexamic acid just prior to surgery reduce the transfusion rate and units transfused when compared to a placebo?</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Osteoarthritis</healthcondition>
    <healthcondition>Avascular necrosis of the femoral head</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>1g Intravenous Tranexamic acid infused ove 10 minutes just prior to surgery.</interventions>
    <comparator>Normal saline 10mls infused over 10minutes just prior to surgery</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Reduction in total units transfused over selected number of patients. From current average of 0.3units per patient to 0.15 units per patient.  Data to be recorded from patient notes</outcome>
      <timepoint>One Week post surgery</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Reduction in blood loss post-operatively.  Using amount of blood drained from subfascial drain left in place for 24 hours.  Data to be taken from patient notes</outcome>
      <timepoint>First 24 hours post surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Reduction in post-operative Haemoglobin drop.  Haemoglobin to be check pre-op and Day 1 post-operatively and Day 5 post-operatively.  Looking for differenced in expected post-operative drop</outcome>
      <timepoint>Five Days post surgery</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Primary total hip replacement
Diagnosis of osteoarthritis or avascular necrosis</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Contraindications for tranexamic acid
Bleeding disorder
Use of Warfarin or Clexane or clopidogrel
History of thromboembolic disorder</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence>Block randomisation using sealed envelopes.  To be opened by those providing the medication sterile.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>6/12/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hawkes Bay</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr James Blackett</primarysponsorname>
    <primarysponsoraddress>Hawkes Bay Hospital
Omahu Road
Hastings 4120
NEW ZEALAND</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Mr Simon Johnson</sponsorname>
      <sponsoraddress>Hawkes Bay Hospital
Omahu Road
Hastings 4120
NEW ZEALAND</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of the study is to reduce the blood transfusion rate after a total hip replacement by giving a medication (tranexamic acid) through the vein just before the operation starts.  This medication has been shown to be safe in most patients in similar studies overseas and is occasionly used in situations of extreme blood loss in New Zealand currently.  It has been shown to reduce blood loss in routine total hip replacements in previous research performed overseas however it's effect on transfusion has not been assesed as a primary outcome. It is not routinely used in New Zealand currently</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>1/09/2010</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr James Blackett</name>
      <address>Hawkes Bay Hospital
Omahu Road
Hastings 4120</address>
      <phone>+64 6 878 8109</phone>
      <fax />
      <email>james.blackett@hawkesbaydhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr James Blackett</name>
      <address>Hawkes Bay Hospital
Omahu Road
Hastings 4120</address>
      <phone>+64 6 878 8109</phone>
      <fax />
      <email>james.blackett@hawkesbaydhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr James Blackett</name>
      <address>Hawkes Bay Hospital
Omahu Road
Hastings 4120</address>
      <phone>+64 6 878 8109</phone>
      <fax />
      <email>james.blackett@hawkesbaydhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>